Compare JWEL & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JWEL | REVB |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.1M |
| IPO Year | 2021 | N/A |
| Metric | JWEL | REVB |
|---|---|---|
| Price | $2.38 | $0.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.7K | ★ 114.0K |
| Earning Date | 11-21-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $132,981,531.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.47 | $0.83 |
| 52 Week High | $3.26 | $60.48 |
| Indicator | JWEL | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 61.17 | 42.53 |
| Support Level | $2.36 | $1.03 |
| Resistance Level | $2.44 | $1.20 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 84.09 | 34.22 |
Jowell Global Ltd is a cosmetics, health, nutritional supplements, and household products e-commerce platform in China. The company offers its branded products to customers and also sells and distributes products from other companies on its platform. In addition, it allows third parties to open their stores on its platform for a service fee based on their sales revenues generated from their online stores and provides them with information about market needs, enabling them to manage their sales effort, as well as an effective platform to promote their brands. The company currently operates under four sales channels: Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing. Geographically, it generates all of its revenue from the PRC.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).